Evidence map›Paper›PMID 38464151›Full record

ArticlebioRxiv : the preprint server for biology2024

Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination.

Jordan Clark, Irene Hoxie, Daniel C Adelsberg, Iden A Sapse, Robert Andreata-Santos, Jeremy S Yong, Fatima Amanat, Johnstone Tcheou, Ariel Raskin, Gagandeep Singh and 9 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 9 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 2 countries.

Jordan ClarkDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Irene HoxieDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Daniel C AdelsbergDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Iden A SapseDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Robert Andreata-SantosDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Jeremy S YongDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Fatima AmanatDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Johnstone TcheouDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Ariel RaskinDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Gagandeep SinghDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Irene González-DomínguezDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Julia E EdgarLaboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY, USA.
Stylianos BournazosLaboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY, USA.
Weina SunDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Juan Manuel CarreñoDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Viviana SimonDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Ali H EllebedyDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.ORCID 0000-0002-6129-2532
Goran BajicDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Florian KrammerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Icahn School of Medicine at Mount Sinai · USRockefeller University · USUniversidade Federal de São Paulo · BRWashington University in St. Louis · US

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH75N93019C00051 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAMMER, FLORIAN · 2019 to 2025
$105.4M
NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00014 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GARCIA-SASTRE, ADOLFO · 2021 to 2025
$62.6M
NCCAT: National Center for CryoEM Access and Training- Supplement for Windows 10 and FFIU24GM129539 · NIGMS · NEW YORK STRUCTURAL BIOLOGY CENTER · PI DE MARCO, ALEX, KIEFT, JEFFREY S · 2018 to 2023
$53.9M
Conduits: Mount Sinai Health System Translational Science HubUL1TR004419 · NCATS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Rosalind J Wright · 2022 to 2026
$46.4M
Viral Immunity and VAccination (VIVA) Human Immunology Project Consortium (HIPC)U19AI168631 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Ana Fernandez-Sesma · 2022 to 2026
$14.4M
Understanding antibody responses and defining correlates of protection for endemic and pandemic coronavirus strainsP01AI172531 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Ali Hassan Ellebedy, Viviana A Simon · 2023 to 2026
$12.5M
Structural interrogation of vaccine- and infection-induced B cell responsesR01AI168178 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Goran Bajic · 2022 to 2026
$3.9M
COVID and Translational Science supercomputer (CATS)S10OD030463 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2021 to 2021
$2.0M
Big Omics Data Engine 2 SupercomputerS10OD026880 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2019 to 2019
$2.0M
NCATS NIH HHS UL1 TR004419NCI NIH HHS 75N91019D00024NIAID NIH HHS 75N93019C00051NIAID NIH HHS 75N93021C00014NIAID NIH HHS P01 AI172531NIAID NIH HHS R01 AI168178NIAID NIH HHS U19 AI168631NIGMS NIH HHS U24 GM129539NIH HHS S10 OD026880NIH HHS S10 OD030463
6 · The paper itself

Abstract

Neutralizing antibodies correlate with protection against SARS-CoV-2. Recent studies, however, show that binding antibody titers, in the absence of robust neutralizing activity, also correlate with protection from disease progression. Non-neutralizing antibodies cannot directly protect from infection but may recruit effector cells thus contribute to the clearance of infected cells. Also, they often bind conserved epitopes across multiple variants. We characterized 42 human mAbs from COVID-19 vaccinated individuals. Most of these antibodies exhibited no neutralizing activity

Identifiers

PMID38464151
PMCPMC10925278
OpenAlexW4392356447

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.